Accord BioPharma Launches FILKRI™ (filgrastim-laha); Now Offers Both Long- and Short-Acting G-CSF Options
FILKRI is available with a permanent Q-code, standardizing the billing and reimbursement process across all sites of care.
RALEIGH, N.C., Oct. 12, 2026 /PRNewswire/ -- Accord BioPharma, Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and central nervous system (CNS) therapies, announced today the U.S. commercial launch of FILKRI™(filgrastim-laha), a biosimilar to Neupogen® (filgrastim). FDA-approved in January 2026, FILKRI represents Accord BioPharma's continued expansion into oncology supportive care and furthers the company's goal to bring 20 biosimilars to the U.S. market by 2030.1
FILKRI is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever; to reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML); to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation; to reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia; and to increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome). FILKRI is available in 300 mcg/0.5 mL and 480 mcg/0.8 mL prefilled syringe presentations, with pack sizes of one or 10 prefilled syringes per carton.1
The addition of FILKRI expands Accord BioPharma's granulocyte colony-stimulating factor (G-CSF) portfolio, giving U.S. physicians access to both short- and long-acting treatment options through FILKRI and UDENYCA® (pegfilgrastim-cbqv). These options help meet the individual needs of patients undergoing chemotherapy and their healthcare providers.2
FILKRI will be manufactured end to end by Accord BioPharma's parent entity, Intas, and has been assigned a permanent Q-code (Q5172) by the U.S. Centers for Medicare & Medicaid Services (CMS), effective October 1, which will standardize the billing and reimbursement process across all sites of care.
"The commercial launch of FILKRI with a permanent Q-code from day one is a significant milestone for Accord BioPharma and for cancer patients across the United States," said Chrys Kokino, President of Accord North America. "Having a permanent Q-code will simplify billing and streamline reimbursement, making it more timely and reliable for physicians treating patients."
Addressing Critical Patient Needs in Neutropenia Management
As a G-CSF, FILKRI is indicated for use across several clinical settings in which neutropenia or its complications may occur, and to increase survival in patients acutely exposed to myelosuppressive doses of radiation. Neutropenia is a condition characterized by lower-than-normal levels of neutrophils, a type of white blood cell that helps the body fight infections. Cancer treatments, including chemotherapy, can damage neutrophils or the bone marrow that produces them.3
"With FILKRI, alongside our established UDENYCA pegfilgrastim franchise, Accord now offers physicians the choice between long-acting and short-acting biosimilar G-CSF treatments to suit their clinical needs and preferences," Kokino added. "This demonstrates our deep commitment to oncology supportive care and positions us as a comprehensive partner for the oncology community."
Filgrastim biosimilars have become well established in the U.S. market, accounting for approximately 77% of filgrastim market share as of the fourth quarter of 2025.4
Expanding Access Through Competitive Pricing and Patient Support
Through AccordCares®, a dedicated patient support program, the company is launching FILKRI with comprehensive patient resources, including benefits investigation and co-pay assistance, designed to connect patients to the information and resources they need, building on the proven foundation established with UDENYCA.
"At Accord, we believe that cost shouldn't prevent patients from receiving the cancer care they need," said Nuvan Dassanaike, Senior Vice President, Digital and Marketing Strategy & Operations, Accord BioPharma. "With FILKRI, we're continuing to build on our track record of bringing high-quality biosimilars to market that provide physicians more choice and can make a real difference in patient care and patient affordability. The permanent Q-code further enhances our ability to expand patient access from launch."
Building on Proven Leadership in Oncology Supportive Care
"The launch of FILKRI in the United States demonstrates our unwavering commitment to building a comprehensive oncology supportive care portfolio that addresses urgent medical needs," said Binish Chudgar, Chairman and Managing Director of Intas Pharmaceuticals. "With the support of Intas, an established global leader with nearly five decades of experience, Accord BioPharma is transforming the conventional treatment landscape by introducing biosimilars to the U.S. market. As our presence in the biosimilar market continues to grow, so does our commitment to offering high-quality, affordable alternatives to reference drugs, so that more patients can access the treatments they need."
FDA approval of FILKRI was based on data demonstrating that FILKRI is highly similar to Neupogen, with no clinically meaningful differences.1
IMPORTANT SAFETY INFORMATION
FILKRI is contraindicated in patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors (G-CSFs) such as filgrastim or pegfilgrastim products.
Splenic Rupture: Splenic rupture, including fatal cases, has been reported following the administration of filgrastim products. Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture.
Acute Respiratory Distress Syndrome (ARDS): ARDS has been reported in patients receiving filgrastim products. Evaluate patients who develop fever and lung infiltrates or respiratory distress for ARDS. Discontinue FILKRI in patients with ARDS.
Serious Allergic Reactions: Serious allergic reactions, including anaphylaxis, have been reported in patients receiving filgrastim products. The majority of reported events occurred upon initial exposure. Provide symptomatic treatment for allergic reactions. Allergic reactions, including anaphylaxis, in patients receiving filgrastim products can recur within days after the discontinuation of initial anti-allergic treatment. Permanently discontinue FILKRI in patients with serious allergic reactions.
Sickle Cell Disorders: Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving filgrastim products. Discontinue FILKRI if sickle cell crisis occurs.
Glomerulonephritis: Has occurred in patients receiving filgrastim products. Diagnoses were based on azotemia, hematuria, proteinuria, and renal biopsy. Generally, events resolved after dose reduction or discontinuation of filgrastim products. If causality is likely, consider dose-reduction or interruption of FILKRI.
Alveolar Hemorrhage and Hemoptysis: Alveolar hemorrhage, manifesting as pulmonary infiltrates and hemoptysis requiring hospitalization, have been reported in FILKRI-treated healthy donors undergoing peripheral blood progenitor cell (PBPC) collection mobilization. Hemoptysis resolved with discontinuation of filgrastim products. The use of FILKRI for PBPC mobilization in healthy donors is not an approved indication.
Capillary Leak Syndrome (CLS): CLS has been reported after G-CSF administration, including filgrastim products and is characterized by hypotension, hypoalbuminemia, edema, and hemoconcentration. Episodes vary in frequency, severity, and may be life-threatening if treatment is delayed. Patients with symptoms should be closely monitored and receive appropriate treatment.
Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML):
Patients with Severe Chronic Neutropenia (SCN): Confirm the diagnosis of SCN before initiating FILKRI therapy. MDS and AML have been reported to occur in the natural history of congenital neutropenia without cytokine therapy. Cytogenetic abnormalities, transformation to MDS, and AML have also been observed in patients treated with filgrastim products for SCN. Abnormal cytogenetics and MDS have been associated with the eventual development of myeloid leukemia. The effect of filgrastim products on the development of abnormal cytogenetics and the effect of continued filgrastim administration in patients with abnormal cytogenetics or MDS are unknown. Monitor patients for signs and symptoms of MDS/AML in these settings. If a patient with SCN develops abnormal cytogenetics or myelodysplasia‚ the risks and benefits of continuing FILKRI should be carefully considered.
Patients with Breast and Lung Cancer: MDS and AML have been associated with the use of filgrastim products in conjunction with chemotherapy and/or radiotherapy in patients with breast and lung cancer. Monitor patients for signs and symptoms of MDS/AML in these settings.
Thrombocytopenia: Thrombocytopenia has been reported in patients receiving filgrastim products. Monitor platelet counts.
Leukocytosis:
Patients with Cancer Receiving Myelosuppressive Chemotherapy: White blood cell counts ≥ 100,000/mm3 were observed in about 2% of patients who received filgrastim products at dosages above 5 mcg/kg/day. Discontinue FILKRI if the absolute neutrophil count (ANC) surpasses 10,000/mm3 after the chemotherapy-induced ANC nadir has occurred. Monitor CBCs at least twice weekly during therapy with FILKRI.
Discontinuation of filgrastim therapy usually resulted in a 50% decrease in circulating neutrophils within 1 to 2 days‚ with a return to pretreatment levels in 1 to 7 days.
Cutaneous Vasculitis: Moderate or severe cases of cutaneous vasculitis has been reported in patients treated with filgrastim products. Most reports involved patients with SCN receiving long-term filgrastim therapy. Hold FILKRI therapy in patients with cutaneous vasculitis. FILKRI dose may be reduced when the symptoms resolve and the ANC has decreased.
Potential Effect on Malignant Cells: FILKRI is a growth factor that primarily stimulates neutrophils. The granulocyte colony-stimulating factor (G-CSF) receptor through which FILKRI acts has also been found on tumor cell lines. The possibility that FILKRI acts as a growth factor for any tumor type cannot be excluded. The safety of filgrastim products in chronic myeloid leukemia (CML) and myelodysplasia has not been established.
Simultaneous Use with Chemotherapy and Radiation Not Recommended: The safety and efficacy of FILKRI given simultaneously with cytotoxic chemotherapy and radiation have not been established. Do not use FILKRI 24 hours before or after administration of cytotoxic chemotherapy. The safety and efficacy of FILKRI have not been evaluated in patients receiving concurrent radiation therapy. Avoid the simultaneous use of FILKRI with chemotherapy and radiation therapy.
Nuclear Imaging: Increased hematopoietic activity of the bone marrow has been associated with transient positive bone-imaging changes on nuclear imaging.
Aortitis: Aortitis has been reported in patients receiving filgrastim products. It may occur as early as the first week after start of therapy. Manifestations may include generalized signs and symptoms such as fever, abdominal pain, malaise, back pain, and increased inflammatory markers (e.g., c-reactive protein and white blood cell count). Consider aortitis in patients who develop these signs and symptoms without known etiology. Discontinue FILKRI if aortitis is suspected.
The most common adverse reactions in patients:
- with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs (≥ 5% difference in incidence compared to placebo) are pyrexia, pain, rash, cough, and dyspnea
- with AML (≥ 2% difference in incidence) are pain, epistaxis and rash
- with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by BMT (≥ 5% difference in incidence) is rash
- with severe chronic neutropenia (SCN) (≥ 5% difference in incidence) are pain, anemia, epistaxis, diarrhea, hypoesthesia and alopecia
INDICATIONS
FILKRI is a leukocyte growth factor indicated to:
- Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever
- Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML)
- Reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT)
- Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia
- Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome) http://www.fda.gov/medwatch
For more information, please see the full Prescribing Information.
About Accord BioPharma
Accord BioPharma, Inc. is the U.S. specialty division of Intas Pharmaceuticals, Ltd., one of the world's most experienced biosimilar developers. Focused on the therapeutic areas of oncology, immunology, and CNS, Accord BioPharma is committed to expanding patient access to high-quality, affordable biologic therapies. The company's FDA-approved commercial portfolio includes UDENYCA® (pegfilgrastim-cbqv) – a biosimilar to NEULASTA® (pegfilgrastim); FILKRI™ (filgrastim-laha) – a biosimilar to NEUPOGEN® (filgrastim); IMULDOSA® (ustekinumab-srlf) – a biosimilar to STELARA® (ustekinumab); HERCESSI™ (trastuzumab-strf) – a biosimilar to HERCEPTIN® (trastuzumab); OSVYRTI® (denosumab-desu) – a biosimilar to Prolia® (denosumab); JUBEREQ® (denosumab-desu) – a biosimilar to Xgeva® (denosumab); ENNUMO™ (pegfilgrastim-pccg) – a biosimilar to NEULASTA® (pegfilgrastim); and CAMCEVI® (leuprolide mesylate) injectable emulsion. Accord BioPharma has received FDA approval on additional products including IMMGOLIS™ (golimumab-sldi) – a biosimilar to Simponi® (golimumab), and IMMGOLIS INTRI™ (golimumab-sldi) – a biosimilar to Simponi Aria® (golimumab). The company's strategic goal is to launch 20 biosimilar products in the U.S. by 2030. For more information, visit www.accordbiopharma.com.
References:
- FILKRI (filgrastim-laha) injection. Prescribing Information. Accord BioPharma.
- UDENYCA Prescribing Information. Coherus BioSciences.
- Cleveland Clinic. Neutropenia. Updated June 9, 2022. Accessed October 2, 2026. https://my.clevelandclinic.org/health/diseases/21058-neutropenia.
- Samsung Bioepis. Biosimilar Market Report. 13th ed., Q2 2026.
All trademarks, logos and brand names are the property of their respective owners.
Contact: [email protected]
SOURCE Accord BioPharma
Share this article